Alia M. Orbin, Ph.D. focuses her practice on intellectual property (IP) matters, including the preparation and prosecution of patent applications, due diligence, patentability, and freedom to operate analyses. Alia’s practice encompasses a variety of technologies related to the life sciences, including small molecule drugs and formulations, organic light emitting diodes, polymers, biotechnology, and material sciences.
Prior to joining Morgan Lewis, Alia was an associate at a Philadelphia-area IP boutique firm. She also worked as a patent agent at an IP boutique firm in the greater Philadelphia area. In addition to her intellectual property background, Alia is an experienced research scientist in organic chemistry. Her graduate work focused on natural product synthesis, and she also worked as a research associate in medicinal chemistry at a pharmaceutical company where she synthesized novel small-molecule antibiotics.
Alia co-authored several peer-reviewed publications, including "(+)-Rimocidin Synthetic Studies: Construction of the C(1−27) Aglycone Skeleton" in the Journal of Organic Chemistry (2009); "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics" in Bioorganic & Medicinal Chemistry Letters (2008); and "Design at the atomic level: Generation of novel hybrid biaryloxazolidinones as promising new antibiotics" in Bioorganic & Medicinal Chemistry Letters (2008). She has also been named as an inventor on multiple patent applications, of which five have been granted as US patents.
Temple University, Beasley School of Law, 2019, J.D., magna cum laude
University of Pennsylvania, 2012, Ph.D., Organic Chemistry